Ergotamine tartrate and caffeine tablets are indicated as a combination therapy to both stop and prevent vascular headaches, migraine headaches and cluster migraines.
Ergotamine is an alpha adrenergic blocking agent that offers a direct stimulating effect on the blood vessels, thus producing a depression of the central vasomotor centers.
Mode of Action:
As part of the ergot alkaloid family, Ergotamine iwas one of the first ergot alkaloids to be isolated. The plentiful vasoconstrictor activities of Ergotamine Tartrate includes positive inhibitory effects on neurogenic inflammation.
Ergotamine is metabolized in the liver with over 90 percent of the metabolites excreted in the bile as a 2 hour half-life.
Over dosage of Ergotamine Tartrate can be a concern and this has been documented. Symptoms of Ergotism, or an overdose of Ergotamine include vomiting, cyanosis, coma, convulsions and shock. While rare, caution should be taken by patients not to overdose on Ergotamine or products containing this drug. Side effects, albeit mild, reported from patients who took Ergotamine include nausea and dizziness.
Headache. 2010.Young, WB. Appropriate use of ergotamine tartrate and dihydroergotamine in the treatment of migraine: current perspectives. Headache. 37 Suppl 1:S42-5, 1997.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.
API’s From Quality Manufacturers:
Cost effective materials based on specific requirements
Small quantities for initial research and larger development quantities towards product commercialization
Technical packages, letters of access to filed DMFs